For patients with KRAS G12C mutated NSCLC, how would you decide between using targeted therapy with sotorasib vs adagrasib?   

Is there anything to differentiate the two agents? CNS penetration reportedly with adagrasib, FDA accelerated approval has been given with sotorasib. 

Phase II publication 

Jänne et al., PMID 35658005 



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice